# APOC3

## Overview
APOC3 is a gene that encodes the protein apolipoprotein C-III (apoC-III), which plays a crucial role in lipid metabolism. This protein is primarily synthesized in the liver and intestines and is a component of various lipoproteins, including very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), and chylomicrons. ApoC-III functions by inhibiting lipoprotein lipase, an enzyme essential for the hydrolysis of triglycerides, thereby regulating triglyceride levels in the bloodstream and influencing the risk of cardiovascular diseases (Tao2016APOC3; Herron2006Associations). The protein's interaction with lipids is facilitated by its structure, which includes several amphipathic Î±-helices essential for binding to lipoproteins (Gangabadage2008Structure; Bolanos-Garcia2003On). Understanding the function and structure of apoC-III is vital for exploring therapeutic targets for lipid-related disorders.

## Structure
APOC3 encodes the apolipoprotein C3, a protein involved in lipid metabolism. The primary structure of APOC3 consists of a 99-amino acid pre-protein, which is processed to a mature form of 79 amino acids after the cleavage of a 20-amino acid signal peptide (Bolanos-Garcia2003On; Jong1999Role). The mature protein undergoes post-translational modifications, notably O-linked sialylation at threonine residue 74, resulting in three isoforms: apoC3-0, apoC3-1, and apoC3-2, which differ in their sialic acid content (Jong1999Role).

The secondary structure of APOC3 includes several amphipathic Î±-helices, crucial for its function and interaction with lipids. Notably, an amphipathic helix spanning residues 50-69 is essential for binding to lipoproteins (Gangabadage2008Structure; Bolanos-Garcia2003On). The tertiary structure, modeled based on homology with other apolipoproteins, suggests a fold similar to apoC-I and apoC-II, with a cluster of residues at the C-terminal end essential for lipoprotein binding (Bolanos-Garcia2003On). No specific quaternary structure is described in the provided sources.

These structural features, including the specific domains and helical segments, play a significant role in the protein's interaction with plasma lipoproteins and its regulatory effects on lipid metabolism.

## Function
APOC3 encodes apolipoprotein C-III (apoC-III), a protein that plays a pivotal role in lipid metabolism, particularly in the regulation of triglyceride levels in the bloodstream. This protein is primarily synthesized in the liver and, to a lesser extent, in the intestines. ApoC-III is a component of several types of lipoproteins, including very low-density lipoproteins (VLDL), high-density lipoproteins (HDL), and chylomicrons. It functions by inhibiting lipoprotein lipase (LPL), an enzyme crucial for the hydrolysis of triglycerides in these lipoproteins. This inhibition prevents the breakdown of triglycerides, leading to increased plasma triglyceride levels (Tao2016APOC3; Herron2006Associations).

Additionally, apoC-III modulates the hepatic uptake of triglyceride-rich lipoproteins by inhibiting their binding to remnant receptors on the liver. This action contributes to the prolonged circulation of triglycerides in the bloodstream (Ginsberg1986Apolipoprotein). ApoC-III also affects the synthesis and secretion of VLDL in the liver, further influencing plasma lipid levels (Sundaram2010Functional).

The presence of apoC-III on lipoproteins is linked to increased risk of cardiovascular diseases due to its role in maintaining elevated levels of triglycerides and influencing lipid transport and metabolism (Tao2016APOC3). Thus, apoC-III is not only crucial for lipid metabolism but also represents a significant factor in the development of lipid-related disorders.

## Clinical Significance
Mutations in the APOC3 gene, particularly loss-of-function (LoF) mutations, have been associated with significant alterations in lipid metabolism, influencing the risk of coronary artery disease (CAD) and other cardiovascular conditions. Studies have shown that carriers of these mutations, such as the R19X, IVS2+1GâA, and A43T, exhibit lower plasma triglyceride levels and a reduced risk of coronary heart disease and ischemic vascular diseases (2014; JÃ¸rgensen2014Loss-of-Function). These mutations lead to lifelong low levels of nonfasting triglycerides, which are linked to a decreased incidence of ischemic heart disease and ischemic cerebrovascular disease (JÃ¸rgensen2014Loss-of-Function).

Furthermore, the presence of APOC3 LoF mutations correlates with lower coronary artery calcification scores and lower remnant cholesterol levels, suggesting a cardioprotective effect (BorÃ©n2020The). In addition to CAD, alterations in APOC3 expression are implicated in insulin resistance and Î²-cell failure in type 2 diabetes mellitus (T2 DM), highlighting the gene's broader impact on metabolic health (BorÃ©n2020The).

These findings underscore the potential of targeting APOC3 through therapeutic strategies, such as antisense oligonucleotides, to manage and potentially reduce the risk of cardiovascular diseases and related metabolic disorders (JÃ¸rgensen2014Loss-of-Function).

## Interactions
APOC3 encodes apolipoprotein C-III (apoC-III), which interacts with several proteins and nucleic acids, influencing lipid metabolism and triglyceride-rich lipoprotein (TRL) clearance. ApoC-III inhibits lipoprotein lipase (LPL), a key enzyme in triglyceride hydrolysis, by competing for binding on the TRL surface, particularly when apoC-III is in excess over apoC-II (Ramms2018Apolipoprotein). This protein also hinders the clearance of hepatic TRLs by inhibiting their removal via the LDL receptor (LDLR) and LDL receptor-related protein 1 (LRP1) pathways (Ramms2018Apolipoprotein; Gordts2016ApoC-III). Additionally, apoC-III may interfere with apoE binding to these receptors, affecting TRL clearance (Gordts2016ApoC-III).

At the nucleic acid level, insulin downregulates APOC3 expression by promoting the phosphorylation of FOXO1, which prevents its nuclear translocation and binding to the insulin response element within the APOC3 promoter (Ramms2018Apolipoprotein). Furthermore, apoC-III is involved in transient interactions with glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1), crucial for positioning LPL on the luminal surface of capillaries (Ramms2018Apolipoprotein). The glycosylation status of apoC-III, influenced by N-Acetylgalactosamine transferase 2 (Galnt2), also modulates its function in lipid metabolism (Ramms2018Apolipoprotein).


## References


[1. (Ginsberg1986Apolipoprotein) H N Ginsberg, N A Le, I J Goldberg, J C Gibson, A Rubinstein, P Wang-Iverson, R Norum, and W V Brown. Apolipoprotein b metabolism in subjects with deficiency of apolipoproteins ciii and ai. evidence that apolipoprotein ciii inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. Journal of Clinical Investigation, 78(5):1287â1295, November 1986. URL: http://dx.doi.org/10.1172/jci112713, doi:10.1172/jci112713. (342 citations) 10.1172/jci112713](https://doi.org/10.1172/jci112713)

[2. (JÃ¸rgensen2014Loss-of-Function) Anders Berg JÃ¸rgensen, Ruth Frikke-Schmidt, BÃ¸rge G. Nordestgaard, and Anne TybjÃ¦rg-Hansen. Loss-of-function mutations inapoc3and risk of ischemic vascular disease. New England Journal of Medicine, 371(1):32â41, July 2014. URL: http://dx.doi.org/10.1056/nejmoa1308027, doi:10.1056/nejmoa1308027. (716 citations) 10.1056/nejmoa1308027](https://doi.org/10.1056/nejmoa1308027)

[3. (Herron2006Associations) Kristin L. Herron, Ingrid E. Lofgren, Xian Adiconis, Jose M. Ordovas, and Maria Luz Fernandez. Associations between plasma lipid parameters and apoc3 and apoa4 genotypes in a healthy population are independent of dietary cholesterol intake. Atherosclerosis, 184(1):113â120, January 2006. URL: http://dx.doi.org/10.1016/j.atherosclerosis.2005.03.023, doi:10.1016/j.atherosclerosis.2005.03.023. (48 citations) 10.1016/j.atherosclerosis.2005.03.023](https://doi.org/10.1016/j.atherosclerosis.2005.03.023)

[4. (Gangabadage2008Structure) Chinthaka Saneth Gangabadage, Janusz Zdunek, Marco Tessari, Solveig Nilsson, Gunilla Olivecrona, and Sybren Sipke Wijmenga. Structure and dynamics of human apolipoprotein ciii. Journal of Biological Chemistry, 283(25):17416â17427, June 2008. URL: http://dx.doi.org/10.1074/jbc.m800756200, doi:10.1074/jbc.m800756200. (67 citations) 10.1074/jbc.m800756200](https://doi.org/10.1074/jbc.m800756200)

[5. (Bolanos-Garcia2003On) Victor Martin Bolanos-Garcia and Ricardo Nunez Miguel. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Progress in Biophysics and Molecular Biology, 83(1):47â68, September 2003. URL: http://dx.doi.org/10.1016/s0079-6107(03)00028-2, doi:10.1016/s0079-6107(03)00028-2. (122 citations) 10.1016/s0079-6107(03)00028-2](https://doi.org/10.1016/s0079-6107(03)00028-2)

[6. (Tao2016APOC3) Yun Tao, Yisong Xiong, Huimin Wang, Shaopeng Chu, Renqian Zhong, Jianxin Wang, Guihua Wang, Xiumei Ren, and Juan Yu. Apoc3 induces endothelial dysfunction through tnf-Î± and jam-1. Lipids in Health and Disease, September 2016. URL: http://dx.doi.org/10.1186/s12944-016-0326-0, doi:10.1186/s12944-016-0326-0. (28 citations) 10.1186/s12944-016-0326-0](https://doi.org/10.1186/s12944-016-0326-0)

[7. (Sundaram2010Functional) Meenakshi Sundaram, Shumei Zhong, Maroun Bou Khalil, Hu Zhou, Zhenghui G. Jiang, Yang Zhao, Jahangir Iqbal, M. Mahmood Hussain, Daniel Figeys, Yuwei Wang, and Zemin Yao. Functional analysis of the missense apoc3 mutation ala23thr associated with human hypotriglyceridemia. Journal of Lipid Research, 51(6):1524â1534, June 2010. URL: http://dx.doi.org/10.1194/jlr.m005108, doi:10.1194/jlr.m005108. (49 citations) 10.1194/jlr.m005108](https://doi.org/10.1194/jlr.m005108)

[8. (BorÃ©n2020The) Jan BorÃ©n, Chris J. Packard, and Marja-Riitta Taskinen. The roles of apoc-iii on the metabolism of triglyceride-rich lipoproteins in humans. Frontiers in Endocrinology, July 2020. URL: http://dx.doi.org/10.3389/fendo.2020.00474, doi:10.3389/fendo.2020.00474. (112 citations) 10.3389/fendo.2020.00474](https://doi.org/10.3389/fendo.2020.00474)

[9. (Jong1999Role) Miek C. Jong, Marten H. Hofker, and Louis M. Havekes. Role of apocs in lipoprotein metabolism: functional differences between apoc1, apoc2, and apoc3. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(3):472â484, March 1999. URL: http://dx.doi.org/10.1161/01.atv.19.3.472, doi:10.1161/01.atv.19.3.472. (412 citations) 10.1161/01.atv.19.3.472](https://doi.org/10.1161/01.atv.19.3.472)

[10. (2014) Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary Disease (848 citations) 10.1056/nejmoa1307095](https://doi.org/10.1056/nejmoa1307095)

[11. (Ramms2018Apolipoprotein) Bastian Ramms and Philip L.S.M. Gordts. Apolipoprotein c-iii in triglyceride-rich lipoprotein metabolism. Current Opinion in Lipidology, 29(3):171â179, June 2018. URL: http://dx.doi.org/10.1097/mol.0000000000000502, doi:10.1097/mol.0000000000000502. (76 citations) 10.1097/mol.0000000000000502](https://doi.org/10.1097/mol.0000000000000502)

[12. (Gordts2016ApoC-III) Philip L.S.M. Gordts, Ryan Nock, Ni-Huiping Son, Bastian Ramms, Irene Lew, Jon C. Gonzales, Bryan E. Thacker, Debapriya Basu, Richard G. Lee, Adam E. Mullick, Mark J. Graham, Ira J. Goldberg, Rosanne M. Crooke, Joseph L. Witztum, and Jeffrey D. Esko. Apoc-iii inhibits clearance of triglyceride-rich lipoproteins through ldl family receptors. Journal of Clinical Investigation, 126(8):2855â2866, July 2016. URL: http://dx.doi.org/10.1172/jci86610, doi:10.1172/jci86610. (191 citations) 10.1172/jci86610](https://doi.org/10.1172/jci86610)